XL-413

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameXL-413
Drug Alias NameBMS-863233XL-413EXEL-5413
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell division cycle 7-related protein kinase inhibitors
TargetsCell division cycle 7-related protein kinase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyExelixis Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A